Korea’s biotechnology industry is entering a new phase of global ambition. Having established significant capabilities across biopharmaceutical manufacturing, drug development and technology innovation, the country is increasingly positioning its emerging biotech companies for international investment, licensing and strategic partnerships.

That transition was at the centre of the Korea Session, “Why Korea, Why Now? Emerging Investment & Partnership Opportunities in Korean Biotech,” held on July 17 at BIO Asia–Taiwan 2026 in Taipei.

Co-organised by KoreaBIO, the session brought together perspectives from industry, venture capital and business development to examine a question becoming increasingly relevant to the region’s life sciences sector: Can Korea and Taiwan combine their respective strengths to help build the next globally competitive biotechnology growth corridor in Asia?

From Manufacturing Strength to Innovation Ambition

Opening the session, Jurie Hwang, Director of Public & International Affairs at KoreaBIO, outlined the evolution of Korea’s biotechnology ecosystem and the factors making the market increasingly attractive to international partners.

Korea’s established industrial capabilities are now being complemented by a growing generation of biotechnology companies developing innovative therapeutics, technology platforms and healthcare solutions. For global investors and pharmaceutical partners, this evolution is broadening the opportunity beyond manufacturing and creating new pathways for licensing, co-development and cross-border commercialisation.

The discussion also reflected a wider shift taking place across Asian biotechnology. Innovation is becoming increasingly distributed, and companies no longer need to build every capability within a single organisation or market. The ability to identify the right partners—and connect scientific innovation with capital, development expertise and market access—is becoming an increasingly important competitive advantage.

Following the Smart Money

Chun Ji Woong, Managing Director at Woori Venture Partners, brought an investor perspective to the conversation, examining where capital is moving within Korean biotechnology and what investors increasingly expect from emerging companies.

As financing conditions become more selective, compelling science alone may no longer be sufficient to attract sustained investment. Companies must demonstrate a credible development pathway, differentiated technology, commercially relevant assets and a clear understanding of how they intend to compete internationally.

This changing investment environment could ultimately strengthen the Korean biotechnology ecosystem by encouraging companies to think globally earlier in their development journey.

The growing importance of licensing and strategic transactions also signals that investors are looking beyond traditional financing milestones. The potential to establish partnerships with global pharmaceutical companies, validate technology internationally and demonstrate commercial optionality is increasingly central to how biotechnology opportunities are assessed.

Building for Partnership from the Beginning

Offering a company-level perspective, Ahyoung Shin, Director and Head of Business Development at Illimis Therapeutics, addressed the practical realities of building a Korean biotechnology company for global partnership.

For emerging biotech companies, international expansion is rarely a single transaction. It requires sustained relationship-building, strategic positioning and the ability to communicate scientific value in a way that resonates with investors and prospective partners across different markets.

The discussion highlighted the importance of integrating business development into a company’s growth strategy from an early stage. Companies seeking international partnerships must understand not only what makes their technology innovative, but also where it fits within the priorities and pipelines of potential collaborators.

This is particularly relevant as Asian biotechnology companies increasingly compete for attention in a global market where capital and partnership opportunities are highly selective.

Can Korea and Taiwan Build a New Asian Biotech Corridor?

The session culminated in a panel discussion examining the potential for deeper collaboration between Korea and Taiwan.

Moderated by Jurie Hwang, the panel brought together Chun Ji Woong of Woori Venture Partners; Ahyoung Shin of Illimis Therapeutics; Steven Chen, Senior Business Development Manager at Health2Sync; and Portia Lin, Senior Vice President and Chief Business Officer at EirGenix, Inc.

The composition of the panel itself reflected the breadth of potential collaboration—from biotechnology investment and therapeutic innovation to digital healthcare and biopharmaceutical development.

Korea and Taiwan bring different but potentially complementary strengths to the table. Korea has developed considerable scale in biopharmaceuticals and an increasingly ambitious innovation ecosystem, while Taiwan combines strong biomedical research with healthcare technology, manufacturing capabilities and a strategically connected technology sector.

The opportunity is therefore not simply to create more bilateral exchanges. It is to build practical pathways through which companies can access complementary expertise, capital, clinical capabilities, technology and international markets.

Such partnerships could take multiple forms: joint development programmes, cross-border investment, licensing agreements, technology collaborations and shared market-entry strategies.

Asia’s Biotech Opportunity Is Becoming Increasingly Connected

One of the clearest messages emerging from the Korea Session was that the next stage of Asian biotechnology growth is unlikely to be defined by individual markets operating in isolation.

Scientific innovation may originate in one country, financing may come from another, development capabilities may be distributed across several markets, and commercialisation may ultimately be global.

Against this backdrop, the strategic question of “Why Korea, Why Now?” extends beyond Korea itself.

It reflects a broader transformation underway across Asia, where biotechnology ecosystems are becoming more internationally connected and companies are increasingly seeking partners that can complement rather than simply replicate their own capabilities.

For Korea and Taiwan, the opportunity is to translate geographical proximity and complementary strengths into a more structured innovation and investment corridor.

If that happens, the relationship could evolve beyond bilateral cooperation and become part of a wider model for how Asian biotechnology companies collaborate, scale and compete globally.

The next Asian biotech growth hub may ultimately not be defined by a single city or country—but by the strength of the connections built between them.